DaVita
DVA
$193.88
+23.46%
DaVita Inc. is a leading provider of dialysis services, primarily operating in the United States within the Medical Care Facilities industry. As the largest dialysis provider in the U.S. by clinic count, with approximately 35% market share, the company's distinct competitive identity is defined by its massive scale and its unique profit model, which relies heavily on a mix of government (primarily Medicare) and commercial insurance reimbursements. The current investor narrative is dominated by the stock's significant price surge in early February 2026, which has sparked debate over whether this reflects a fundamental re-rating based on improved operational outlook, a reaction to specific corporate or regulatory catalysts, or a broader market rotation into defensive healthcare names.…
DVA
DaVita
$193.88
Related headlines
Investment Opinion: Should I buy DVA Today?
Rating & Thesis: DaVita is a Hold. The core thesis is that the stock's compelling forward valuation and cash-generative business are balanced by significant margin pressure and technical overextension following a parabolic advance. The mixed analyst sentiment (from Underperform to Buy) reflects this uncertainty, and without a clear average target price, the implied upside is ambiguous.
Supporting Evidence: The primary valuation metric, the forward P/E of 9.25x, is attractive and suggests embedded earnings growth, with analyst EPS estimates averaging $18.12. Revenue growth remains steady at ~10% YoY. However, the declining gross margin trend (down nearly 500 bps in two quarters) is a major red flag. The company's financial strength is evidenced by substantial TTM FCF of $1.31 billion, but this is offset by the leveraged, negative-equity balance sheet. Compared to sector averages, the EV/EBITDA of 9.11x appears reasonable but not a clear bargain.
Risks & Conditions: The two biggest risks are further gross margin erosion and a technical reversal from overbought levels. This Hold rating would upgrade to a Buy if the company demonstrates gross margin stabilization above 30% in the next quarter, confirming the cost pressure is transitory. It would downgrade to a Sell if revenue growth decelerates below 5% or if the stock breaks below key support at $140, invalidating the recent breakout. Relative to its own historical P/E range and current fundamentals, the stock appears fairly valued, neither offering a significant margin of safety nor trading at an excessive premium.
Sign up to view all
DVA 12-Month Price Forecast
DaVita presents a classic 'show me' story. The valuation is undemanding and the business model is cash-generative and defensive, which is attractive. However, the investment thesis hinges entirely on the company's ability to arrest and reverse the troubling gross margin decline. The recent powerful price move appears to have priced in a positive outcome, leaving limited margin for error. The stance is neutral with medium confidence, as the next 1-2 quarters are critical for confirming the margin trajectory. An upgrade to bullish would require clear evidence of margin stabilization; a downgrade to bearish would be triggered by another quarter of material compression or a break of key technical support.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on DaVita's 12-month outlook, with a consensus price target around $252.04 and implied upside of +30.0% versus the current price.
Average Target
$252.04
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$155 - $252
Analyst target range
Analyst coverage for DaVita appears limited, with data indicating only 2 analysts providing estimates. The consensus sentiment, inferred from recent institutional ratings, is neutral to cautious. Recent actions include a 'Buy' reiteration from UBS and an 'Equal Weight' from Barclays in February 2026, alongside an 'Underperform' from B of A Securities in September 2025. The average target price is not explicitly provided in the data, and the estimated EPS range is $17.77 to $18.76. Without a clear consensus price target, calculating implied upside is not possible. The available data suggests insufficient broad analyst coverage to derive a strong consensus view. This limited coverage is typical for a company of DaVita's profile—a large-cap but in a niche, specialized healthcare sector—and can lead to higher volatility and less efficient price discovery, as the stock may be more influenced by dedicated sector funds and generalist investors reacting to quarterly results rather than a deep bench of ongoing analyst scrutiny. The recent price surge in February 2026 occurred without a corresponding wave of analyst upgrades in the provided data, indicating the move may have been driven by other factors, such as institutional positioning or macroeconomic shifts.
Bulls vs Bears: DVA Investment Factors
The bull case, centered on strong cash flow, defensive growth, and a compelling forward valuation, currently holds stronger evidence, supported by the stock's powerful fundamental re-rating. However, the bear case presents serious near-term risks, primarily the concerning trend of gross margin compression and the stock's technical overextension following a 38.7% surge. The single most important tension in the investment debate is whether the company's robust free cash flow and scale advantages can sustainably offset the clear margin pressures and balance sheet risks. The resolution of this margin trend will be the primary determinant of whether the recent price breakout marks a new sustainable uptrend or a temporary peak.
Bullish
- Strong Free Cash Flow Generation: DaVita generates robust free cash flow, with TTM FCF of $1.31 billion. This cash-generative profile supports shareholder returns through buybacks and provides a buffer for its leveraged balance sheet, a key attraction for value-oriented investors.
- Attractive Forward Valuation: The stock trades at a forward P/E of 9.25x, a significant discount to its trailing P/E of 13.10x, implying strong expected earnings growth. This forward multiple is low for a profitable healthcare services company with stable demand.
- Essential Service with Steady Growth: Revenue grew 9.87% YoY in Q4 2025 to $3.62 billion, demonstrating consistent, single-digit growth. The dialysis business provides an essential, non-discretionary service, offering defensive characteristics and predictable revenue streams.
- Market Leadership and Scale: With approximately 35% U.S. market share and over 3,000 clinics, DaVita's massive scale provides significant operational and cost advantages. This entrenched position creates a high barrier to entry for competitors.
Bearish
- Gross Margin Compression Trend: Gross margin has declined sequentially from 33.08% in Q2 2025 to 28.28% in Q4 2025. This 480 basis point contraction over two quarters indicates rising cost pressures or a less favorable reimbursement mix, directly threatening profitability.
- Highly Leveraged, Distorted Balance Sheet: The company has a negative debt-to-equity ratio of -23.12 and negative shareholder equity, a result of aggressive share buybacks. This highly leveraged capital structure increases financial risk, especially in a rising interest rate environment.
- Consolidation After Parabolic Move: The stock is up only 0.87% over the past month, significantly underperforming the S&P 500 by -9.11%. Trading at 95% of its 52-week high ($159.42), the recent consolidation suggests the explosive February rally may have been overdone, posing a near-term pullback risk.
- Heavy Dependence on Government Payers: Approximately two-thirds of U.S. sales come from government reimbursements (primarily Medicare), which are subject to political and budgetary pressures. This reliance creates regulatory risk and caps pricing power, with commercial insurers generating nearly all profits.
DVA Technical Analysis
The prevailing price trend for DaVita is a powerful recovery and uptrend, characterized by a dramatic breakout in early February 2026. The stock has gained 7.98% over the past year, but this masks a much more aggressive 38.70% surge over the last three months. As of the latest close at $151.65, the stock is trading at approximately 95% of its 52-week high of $159.42, positioning it near the top of its annual range. This proximity to highs suggests strong momentum but also raises questions about potential overextension, especially given the sharp ascent from its 52-week low of $101.00. Recent short-term momentum shows a slight deceleration from the explosive February move, with the stock up only 0.87% over the past month. This 1-month performance significantly lags the S&P 500's 9.98% gain, resulting in a stark negative relative strength of -9.11%, indicating the stock is consolidating after its major run. The divergence between the strong 3-month surge and the tepid 1-month move suggests a period of digestion or profit-taking following the parabolic advance. Key technical levels are clearly defined by the 52-week high of $159.42 as immediate resistance and the 52-week low of $101.00 as major support. A decisive breakout above $159.42 would signal a continuation of the bullish trend, while a breakdown below the recent consolidation range could target lower support levels. The stock's beta of 0.915 indicates it is slightly less volatile than the broader market, which is notable given the recent price explosion; this low beta suggests the recent move may be driven by idiosyncratic, company-specific factors rather than sector-wide momentum.
Beta
0.84
0.84x market volatility
Max Drawdown
-33.2%
Largest decline past year
52-Week Range
$101-$194
Price range past year
Annual Return
+35.9%
Cumulative gain past year
| Period | DVA Return | S&P 500 |
|---|---|---|
| 1m | +29.1% | +11.4% |
| 3m | +29.9% | +8.3% |
| 6m | +56.7% | +9.4% |
| 1y | +35.9% | +31.3% |
| ytd | +69.3% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DVA Fundamental Analysis
DaVita's revenue trajectory shows steady, single-digit growth. For Q4 2025, the company reported revenue of $3.62 billion, representing a year-over-year growth of 9.87%. This growth rate appears consistent, as quarterly revenues have climbed sequentially from $3.22 billion in Q1 2025 to the latest figure. The sole reported segment, 'U.S. Dialysis and Related Lab Services,' generated $10.12 billion over an unspecified period, confirming the business remains concentrated in its core service line. This stable, predictable revenue stream is characteristic of the essential nature of dialysis care. The company is profitable, with Q4 2025 net income of $234.2 million and a net margin of 6.47%. Gross margin for the quarter was 28.28%, while the operating margin stood at 15.24%. Profitability has been consistent, though margins show some quarterly variability; for instance, the gross margin of 28.28% in Q4 2025 is down from 31.80% in Q3 2025 and 33.08% in Q2 2025. This compression in gross profit ratio suggests potential cost pressures or reimbursement mix shifts, which is a critical area for monitoring in this reimbursement-sensitive business. DaVita demonstrates robust financial health and cash generation. The company's trailing twelve-month free cash flow is a substantial $1.31 billion. The current ratio of 1.29 indicates adequate short-term liquidity. However, the balance sheet carries significant leverage, as evidenced by a negative debt-to-equity ratio of -23.12; this negative figure is an accounting artifact stemming from negative shareholder equity, a known characteristic of DaVita's capital structure due to historical share buybacks. The return on equity is also deeply negative at -114.70%, further distorted by the negative equity base. The strong free cash flow, which supports continued share repurchases as seen in the cash flow statements, is the primary indicator of financial strength, allowing the company to service its debt and return capital to shareholders.
Quarterly Revenue
$3.6B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.28%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DVA Overvalued?
Given DaVita's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 13.10x, while the forward PE is notably lower at 9.25x. This significant gap implies the market expects a meaningful increase in earnings over the next twelve months, aligning with the analyst consensus EPS estimate of $18.12. Compared to sector averages, DaVita's valuation presents a mixed picture. Its trailing PE of 13.10x is likely at a discount to many growth-oriented healthcare services peers, but its Price-to-Sales ratio of 0.72x and EV-to-Sales of 1.79x are more relevant for a capital-intensive, stable-margin business like dialysis. The EV-to-EBITDA of 9.11x is a standard sector multiple, suggesting the market is pricing the company in line with its cash-generative profile, without assigning a significant growth premium. Historically, DaVita's current trailing PE of 13.10x sits well below its own historical range observed in the provided data, which has seen periods with PEs above 15x and even above 20x. For instance, in Q3 2023, the historical PE was 8.75x, and it reached 24.70x in Q4 2022. Trading near the middle-to-lower end of its own historical band suggests the stock is not priced for excessive optimism, potentially leaving room for multiple expansion if operational performance improves or if the market reappraises the stability of its cash flows.
PE
13.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~25x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: DaVita's financial risk is pronounced, centered on a highly leveraged capital structure with negative shareholder equity (-23.12 Debt-to-Equity) and a deeply negative ROE of -114.70%. While strong TTM FCF of $1.31 billion services this debt, a sustained rise in interest expenses or a drop in cash generation could strain finances. Operationally, the sequential decline in gross margin from 33.08% to 28.28% over the last two quarters signals acute cost inflation or adverse reimbursement shifts, directly threatening the 6.47% net margin. Revenue concentration in U.S. dialysis, while stable, offers limited diversification if the core market is disrupted.
Market & Competitive Risks: The stock's recent 38.7% surge to $151.65 places it near its 52-week high, creating valuation compression risk if growth expectations are not met. Its forward P/E of 9.25x, while low, could contract further if margin pressures persist. The business faces perennial regulatory risk, as government payers (Medicare) fund the majority of revenue, making it sensitive to healthcare policy changes. Despite a low beta of 0.915, the stock has shown high idiosyncratic volatility, as evidenced by the February breakout, making it susceptible to sharp reversals on company-specific news. Competitive risks are moderated by its 35% market share but remain from integrated health systems and potential innovation in kidney disease treatment.
Worst-Case Scenario: The most damaging scenario involves a continuation of gross margin compression coupled with a regulatory cut to Medicare reimbursement rates. This would trigger a simultaneous earnings miss and multiple contraction, leading analysts to downgrade estimates. A loss of investor confidence could precipitate a rapid unwind of the recent gains. The realistic downside would be a return to the 52-week low of $101.00, representing a potential loss of approximately -33% from the current price of $151.65. This aligns with the stock's historical maximum drawdown of -33.21%, indicating this level of decline is within the realm of historical precedent during periods of stress.
FAQ
The key risks are, in order of severity: 1) Financial Risk: A highly leveraged balance sheet with negative shareholder equity (D/E: -23.12) increases vulnerability to rising rates. 2) Operational Risk: Significant gross margin compression, falling from 33.08% to 28.28% over two quarters, threatens profitability. 3) Regulatory Risk: Dependence on government payers (~66% of sales) subjects the company to potential Medicare reimbursement cuts. 4) Technical Risk: The stock is consolidating after a parabolic 38.7% advance and is trading near its 52-week high, increasing near-term pullback risk if momentum falters.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees the stock trading between $150 and $165, assuming steady execution and margin stabilization. The Bull Case (30% probability) targets $175 to $190 on successful cost management and multiple expansion. The Bear Case (20% probability) warns of a drop to between $101 and $130 if margin pressures worsen and the technical breakout fails. The Base Case is most likely, anchored by analyst EPS estimates averaging $18.12. The key assumption is that gross margin erosion halts, preventing an earnings derailment.
DVA appears fairly valued to slightly undervalued based on forward earnings. The forward P/E of 9.25x represents a significant discount to the trailing P/E of 13.10x, implying the market expects strong earnings growth. Compared to sector averages, its EV/EBITDA of 9.11x is in line with peers. Historically, its trailing P/E of 13.10x is in the middle-to-lower end of its own range, which has seen peaks above 20x. The valuation implies the market is paying a fair price for stable growth but is discounting the stock for margin risks and leverage, rather than assigning a premium for its market leadership.
DVA is a conditional buy for value-oriented, patient investors. The forward P/E of 9.25x is attractive for a company with ~10% revenue growth and $1.31B in annual free cash flow. However, it comes with significant risks: gross margin compression, a leveraged balance sheet, and a stock price that has already surged 38.7% in three months. It is a good buy for those who believe management can stabilize margins, making it suitable for a diversified portfolio with a medium-term horizon. It is not a good buy for risk-averse investors or those seeking short-term gains, given the potential for a sharp pullback.
DVA is more suitable for a medium-to-long-term investment horizon (2+ years) rather than short-term trading. Its low beta (0.915) and essential service model provide stability for long-term holders, while the resolution of margin issues will take several quarters to assess. The stock does not pay a dividend, so total return relies on capital appreciation and buybacks. Short-term traders face heightened risk due to the stock's recent explosive move and current consolidation, which could lead to volatile swings around earnings. Investors should be prepared to hold through potential near-term volatility to realize the value proposition.